Infectious Disease in the Blood Supply and the Public Health Response

Seminars in Hematology

Volumn 43, Issue SUPPL. 3, 2006, Pages

  Evatt, Bruce ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS C ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ARTICLE; BLOOD BANK; BLOOD TRANSFUSION; DECISION MAKING; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEMOPHILIA; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS; IMMUNOASSAY; INFECTION RISK; LONGEVITY; MEDICAL DECISION MAKING; PATIENT EDUCATION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; QUALITY OF LIFE; RISK ASSESSMENT; SAFETY; SCREENING TEST; SEROLOGY; SYPHILIS; VIRAL CONTAMINATION; VIRUS INACTIVATION; VIRUS INFECTION; VIRUS TRANSMISSION; VIRUS VIRULENCE; WEST NILE FLAVIVIRUS;

BLOOD TRANSFUSION; BLOOD-BORNE PATHOGENS; DISEASE TRANSMISSION, HORIZONTAL; HEALTH POLICY; HEMOPHILIA A; HEPATITIS; HISTORY, 20TH CENTURY; HIV INFECTIONS; HUMANS; PUBLIC HEALTH; QUALITY OF HEALTH CARE; SOCIAL RESPONSIBILITY; VIRUS INACTIVATION;

EID: 33646073416     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2006.02.001     Document Type: Article

References (29)

1. Jones P.K., and Ratnoff O.D. The changing prognosis of classic hemophilia (factor VIII "deficiency"). Ann Intern Med 114 (1991) 641-648
2. Public Health Service Act (1975) Section 606 of P.L. 94-63 amended Title XI of the Public Health Service Act
3. Soucie J.M., Nuss R., Evatt B., Abdelhak A., Cowan L., Hill H., et al. Mortality among males with hemophilia with source of medical care. Blood 96 (2000) 437-442
4. Troisi C.L., Hollinger F.B., Hoots W.K., Contant C., Gill J., Ragni M., et al. A multicenter study of viral hepatitis in the United States hemophilic population. Blood 81 (1993) 412-418
5. American Association of Blood Banks: Frequently Asked Questions. Available at: http://www.aabb.org/All_About_Blood/FAQs/aabb_faqs.htm, accessed December 2005
6. In: Leveton L.B., Sox Jr. H.C., and Stoto M.A. (Eds). HIV and the Blood Supply. An Analysis of Crisis Decisionmaking (1995), National Academy Press, Washington, DC
7. Centers for Disease Control and Prevention. Epidemiologic notes and reports Pneumocystis carinii pneumonia among persons with hemophilia A. MMWR Morb Mortal Wkly Rep 31 (1982) 365-367
8. Centers for Disease Control and Prevention. Human immunodeficiency virus infection in the United States. A review of current knowledge. MMWR Morb Mortal Wkly Rep 36 (1987) 1-20
9. Chorba T.L., Holman R.C., Clarke M.J., and Evatt B.L. Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States. Am J Hematol 66 (2001) 229-240
10. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Workshop on factor VIII inhibitors (2003). http://www.fda.gov/cber/minutes/fctrviii112103t.pdf Proceedings of the Food and Drug Administration International Association of Biologicals Workshop on Factor VIII Inhibitors; November 21; Bethesda, MD. Available at www.fda.gov/cber/minutes/fctrviii112103t.pdf, accessed December 2005
11. Josić D., Buchacher A., Kannicht C., Lim Y.P., Loster K., Pock K., et al. Degradation products of factor VIII which can lead to increased immunogenicity. Vox Sang 77 suppl 1 (1999) 90-99
12. McDougal J.S., Martin L.S., Cort S.P., Mozen M., Heldebrant C.M., and Evatt B.L. Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor. J Clin Invest 76 (1985) 875-877
13. Food and Drug Administration. FDA Approves First Nucleic Acid Test (NAT) Systems to Screen Plasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) (2001), National Press Office, Rockville, MD September 21. Talk Paper T01-42
14. Soucie J.M., Richardson L.C., Evatt B.L., Linden J.V., Ewenstein B.M., Stein S.F., et al. Risk factors for infection with HBV and HCV in a large cohort of hemophiliac males. Transfusion 41 (2001) 338-343
15. American Red Cross: How blood is tested. Available at http://www.pleasegiveblood.org/education/blood_tested.php, accessed December 2005
16. Busch M.P., Kleinman S.H., and Nemo G.J. Current and emerging infectious risks of blood transfusions. JAMA 289 (2003) 959-962
17. Schreiber G.B., Busch M.P., Kleinman S.H., Korelitz J.J., and Retrovirus Epidemiology Donor Study. The risk of transfusion-transmitted viral infections. N Engl J Med 336 (1996) 1685-1690
18. Teitel J.M. Viral safety of haemophilia treatment products. Ann Med 32 (2000) 485-492
19. Burnouf T., and Radosevich M. Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia 9 (2003) 24-37
20. Ananyeva N., Khrenov A., Darr F., Summers R., Sarafanov A., and Saenko E. Treating haemophilia A with recombinant blood factors. A comparison. Expert Opin Pharmacother 5 (2004) 1061-1070
21. Schlesinger K.W., and Ragni M.V. Safety of the new generation recombinant factor concentrates. Expert Opin Drug Saf 1 (2002) 213-223
22. Van der Poel C.L., Siefried E., and Schaasberg W.P. Paying for blood donations. Still a risk?. Vox Sang 83 (2002) 385-293
23. Evatt B.L., Austin H., Leon G., Ruiz-Saez A., and De Bosch N. Predicting the long-term risk of HIV exposure by cryoprecipitate. Haemophilia 6 suppl 1 (2000) 128-132
24. Dodd R.Y. Emerging infections, transfusion safety, and epidemiology. N Engl J Med 349 (2003) 1205-1206
25. Llewelyn C.A., Hewitt P.E., Knight R.S., Amar K., Cousens S., Mackenzie J., et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 363 (2004) 417-421
26. Peden A.H., Head M.W., Ritchie D.L., Bell J.E., and Ironside J.W. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364 (2004) 527-529
27. Department of Health. Assessing the risk of vCJD transmission via surgery. An interim review (2005). http://www.dh.gov.uk/assetRoot/04/11/35/42/04113542.pdf March. Available at: http://www.dh.gov.uk/assetRoot/04/11/35/42/04113542.pdf, accessed December 2005
28. Department of Health. Guidance on local reporting by clinicians of Creutzfeldt-Jakob Disease (CJD) and local action by consultants in communicable disease control (CsCDC) (2003). http://www.cjd.ed.ac.uk/guidance.htm November. Available at: http://www.cjd.ed.ac.uk/guidance.htm, accessed December 2005
29. Department of Health. Assessing the implications for blood donors if recipients are infected with vCJD (2005). http://www.dh.gov.uk/assetRoot/04/11/53/12/04115312.pdf July. Available at: http://www.dh.gov.uk/assetRoot/04/11/53/12/04115312.pdf, accessed December 2005